Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
Type of Medium
Language
Region
Years
Person/Organisation
Subjects(RVK)
Access
  • 1
    Online Resource
    Online Resource
    Cham :Springer International Publishing,
    UID:
    edoccha_BV047951549
    Format: 1 Online-Ressource (XVIII, 300 Seiten).
    Edition: 1st edition
    ISBN: 978-3-030-86778-2
    Series Statement: Munich Studies on Innovation and Competition Volume 16
    Content: This book draws a unique perspective on the regulation of access to clinical trial data as a case on research and knowledge externalities. Notwithstanding numerous potential benefits for medical research and public health, many jurisdictions have struggled to ensure access to clinical trial data, even at the level of the trial results. Pro-access policy initiatives have been strongly opposed by research-based drug companies arguing that mandatory data disclosure impedes their innovation incentives. Conventionally, access to test data has been approached from the perspective of transparency and research ethics. The book offers a complementary view and considers access to individual patient-level trial data for exploratory analysis as a matter of research and innovation policy. Such approach appears to be especially relevant in the data-driven economy where digital data constitutes a valuable economic resource. The study seeks to define how the rules of access to clinical trial data should be designed to reconcile the policy objectives of leveraging the research potential of data through secondary analysis, on the one hand, and protecting economic incentives of research-based drug companies, on the other hand. Overall, it is argued that the mainstream innovation-based justification for exclusive control over the outcomes of research and development can hardly rationalise trial sponsors' control over primary data from trials. Instead, access to such data and its robust analysis should be prioritised
    Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-030-86777-5
    Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 9783030867799
    Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 9783030867805
    Language: English
    Subjects: Law
    RVK:
    RVK:
    Keywords: Reproduktionsmedizin ; Embryo ; Schutz ; Forschung ; Biotechnologie ; Reproduktionsmedizin ; Recht ; Hochschulschrift
    URL: Volltext  (URL des Erstveröffentlichers)
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    Online Resource
    Online Resource
    Cham :Springer International Publishing,
    UID:
    edocfu_BV047951549
    Format: 1 Online-Ressource (XVIII, 300 Seiten).
    Edition: 1st edition
    ISBN: 978-3-030-86778-2
    Series Statement: Munich Studies on Innovation and Competition Volume 16
    Content: This book draws a unique perspective on the regulation of access to clinical trial data as a case on research and knowledge externalities. Notwithstanding numerous potential benefits for medical research and public health, many jurisdictions have struggled to ensure access to clinical trial data, even at the level of the trial results. Pro-access policy initiatives have been strongly opposed by research-based drug companies arguing that mandatory data disclosure impedes their innovation incentives. Conventionally, access to test data has been approached from the perspective of transparency and research ethics. The book offers a complementary view and considers access to individual patient-level trial data for exploratory analysis as a matter of research and innovation policy. Such approach appears to be especially relevant in the data-driven economy where digital data constitutes a valuable economic resource. The study seeks to define how the rules of access to clinical trial data should be designed to reconcile the policy objectives of leveraging the research potential of data through secondary analysis, on the one hand, and protecting economic incentives of research-based drug companies, on the other hand. Overall, it is argued that the mainstream innovation-based justification for exclusive control over the outcomes of research and development can hardly rationalise trial sponsors' control over primary data from trials. Instead, access to such data and its robust analysis should be prioritised
    Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-030-86777-5
    Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 9783030867799
    Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 9783030867805
    Language: English
    Subjects: Law
    RVK:
    RVK:
    Keywords: Reproduktionsmedizin ; Embryo ; Schutz ; Forschung ; Biotechnologie ; Reproduktionsmedizin ; Recht ; Hochschulschrift
    URL: Volltext  (URL des Erstveröffentlichers)
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    Online Resource
    Online Resource
    Cham :Springer International Publishing,
    UID:
    almafu_BV047951549
    Format: 1 Online-Ressource (XVIII, 300 Seiten).
    Edition: 1st edition
    ISBN: 978-3-030-86778-2
    Series Statement: Munich Studies on Innovation and Competition Volume 16
    Content: This book draws a unique perspective on the regulation of access to clinical trial data as a case on research and knowledge externalities. Notwithstanding numerous potential benefits for medical research and public health, many jurisdictions have struggled to ensure access to clinical trial data, even at the level of the trial results. Pro-access policy initiatives have been strongly opposed by research-based drug companies arguing that mandatory data disclosure impedes their innovation incentives. Conventionally, access to test data has been approached from the perspective of transparency and research ethics. The book offers a complementary view and considers access to individual patient-level trial data for exploratory analysis as a matter of research and innovation policy. Such approach appears to be especially relevant in the data-driven economy where digital data constitutes a valuable economic resource. The study seeks to define how the rules of access to clinical trial data should be designed to reconcile the policy objectives of leveraging the research potential of data through secondary analysis, on the one hand, and protecting economic incentives of research-based drug companies, on the other hand. Overall, it is argued that the mainstream innovation-based justification for exclusive control over the outcomes of research and development can hardly rationalise trial sponsors' control over primary data from trials. Instead, access to such data and its robust analysis should be prioritised
    Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-030-86777-5
    Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 9783030867799
    Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 9783030867805
    Language: English
    Subjects: Law
    RVK:
    RVK:
    Keywords: Reproduktionsmedizin ; Embryo ; Schutz ; Forschung ; Biotechnologie ; Reproduktionsmedizin ; Recht ; Hochschulschrift
    URL: Volltext  (URL des Erstveröffentlichers)
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    UID:
    gbv_1782164421
    Format: xviii, 300 Seiten
    ISBN: 9783030867775 , 3030867773
    Series Statement: Munich studies on innovation and competition volume 16
    Note: Dissertation Universität Augsburg 2021
    Additional Edition: ISBN 9783030867782
    Additional Edition: Erscheint auch als Online-Ausgabe Kim, Daria Access to Non-Summary Clinical Trial Data for Research Purposes Under EU Law Cham : Springer International Publishing, 2021 ISBN 9783030867782
    Language: English
    RVK:
    Keywords: Hochschulschrift
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 5
    Book
    Book
    Salzburg : Verl. St. Peter
    UID:
    gbv_303086777
    Format: 15 S , Ill , 17 cm
    Edition: 1. Aufl
    Series Statement: Christliche Kunststätten Österreichs 330
    Language: German
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 6
    Online Resource
    Online Resource
    Cham : Springer International Publishing
    UID:
    b3kat_BV047951549
    Format: 1 Online-Ressource (XVIII, 300 Seiten)
    Edition: 1st edition
    ISBN: 9783030867782
    Series Statement: Munich Studies on Innovation and Competition Volume 16
    Content: This book draws a unique perspective on the regulation of access to clinical trial data as a case on research and knowledge externalities. Notwithstanding numerous potential benefits for medical research and public health, many jurisdictions have struggled to ensure access to clinical trial data, even at the level of the trial results. Pro-access policy initiatives have been strongly opposed by research-based drug companies arguing that mandatory data disclosure impedes their innovation incentives. Conventionally, access to test data has been approached from the perspective of transparency and research ethics. The book offers a complementary view and considers access to individual patient-level trial data for exploratory analysis as a matter of research and innovation policy. Such approach appears to be especially relevant in the data-driven economy where digital data constitutes a valuable economic resource. The study seeks to define how the rules of access to clinical trial data should be designed to reconcile the policy objectives of leveraging the research potential of data through secondary analysis, on the one hand, and protecting economic incentives of research-based drug companies, on the other hand. Overall, it is argued that the mainstream innovation-based justification for exclusive control over the outcomes of research and development can hardly rationalise trial sponsors' control over primary data from trials. Instead, access to such data and its robust analysis should be prioritised
    Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-030-86777-5
    Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 9783030867799
    Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 9783030867805
    Language: English
    Subjects: Law
    RVK:
    RVK:
    Keywords: Deutschland ; Reproduktionsmedizin ; Embryo ; Schutz ; Forschung ; Biotechnologie ; Deutschland ; Reproduktionsmedizin ; Recht ; Hochschulschrift
    URL: Volltext  (URL des Erstveröffentlichers)
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Did you mean 3030867773?
Did you mean 300326777?
Did you mean 303006277?
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages